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Abstract
Background: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar
degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in
patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment.
Methods: In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and <60 IU/mL,
respectively, following entecavir (0.5 mg/day) treatment for HBeAg-positive chronic hepatitis B were randomized to
either switch treatment to telbivudine (600 mg/day, n = 47) or continue entecavir (n = 50) for 48 weeks.
Results: The baseline characteristics were comparable between groups including HBsAg levels (median, 3.41
log10 IU/mL). All patients had undetectable HBV DNA and normal alanine aminotransferase level. At week 48,
the mean change in serum HBsAg levels was not significantly different between the telbivudine and entecavir
groups (−0.03 log10 IU/mL vs. −0.05 log10 IU/mL; P = 0.57). No patient experienced HBsAg seroclearance or HBsAg
decline >0.5 log10 IU/mL. Eleven patients (23.4%) in the telbivudine group, but none in the entecavir group,
experienced virologic breakthrough (P < 0.001). Seven patients (14.9%) exhibited genotypic resistance mutations
(M204I +/− L180M) during the virologic breakthrough.
Conclusion: Sequential therapy with entecavir followed by telbivudine resulted in a high rate of virologic
breakthrough and drug-resistance without any beneficial effect on HBsAg decline. These results do not support
the use of low genetic barrier drugs as a switch treatment strategy in patients who achieve virologic response
with high genetic barrier drugs.
Trial registration: NCT01595685 (date of trial registration: May 8, 2012)
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Background
Approximately 400 million people worldwide are chron-
ically infected with hepatitis B virus (HBV). These pa-
tients have a substantially increased risk of cirrhosis and
hepatocellular carcinoma (HCC), which are responsible
for approximately 1 million deaths worldwide annually
[1, 2]. The availability of potent nucleos(t)ide analogs
(NUC) such as entecavir and tenofovir disoproxil
fumarate (TDF) has made the suppression of serum
HBV DNA to levels undetectable by polymerase chain
reaction (PCR) assays achievable in most patients, with a
minimal risk of drug-resistance [3, 4]. However, the
eradication of HBV, which is best indicated by serum
hepatitis B surface antigen (HBsAg) seroclearance, is
rarely achievable with long-term NUC therapy [5–9].
The discontinuation of treatment before HBsAg sero-
clearance is associated with high rate of hepatitis relapse
and disease progression [10, 11]. Therefore, treatments
that can induce a rapid decline in HBsAg levels would
have a clear advantage in reducing the treatment
duration required to achieve HBsAg seroclearance.
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Treatment with pegylated-interferon (PEG-IFN) has
been reported to be associated with a greater HBsAg
decline than NUC-treatment in patients with chronic
HBV infection (CHB), regardless of hepatitis B envelope
antigen (HBeAg) positivity [12, 13]. Interestingly, recent
preliminary study demonstrated that telbivudine, a
nucleoside analog, was associated with rapid HBsAg de-
cline that was comparable to that induced by PEG-IFN
in patients with HBeAg-positive CHB [14]. Although
there has been no head-to-head trial comparing the
induction of HBsAg decline by different NUCs, previous
studies have repeatedly suggested that the decline in
HBsAg may be greater during telbivudine treatment
than it is with lamivudine or entecavir [12, 15–17].
Although telbivudine is associated with a relatively high
rate of resistance, the risk could be reduced by profound
early viral suppression to undetectable levels [18, 19].
In this randomised trial, we aimed to determine whether
telbivudine induces a decline in HBsAg levels to a differ-
ent degree compared with entecavir in patients with
HBeAg-positive CHB, who have achieved undetectable
serum HBV DNA levels by previous entecavir treatment.
Methods
Study design
This study was a randomized open-label trial (Clinical-
Trials.gov ID NCT01595685; TERESA study) conducted
in patients who had achieved a virologic response
(serum HBV DNA <15 IU/mL) by preceding entecavir
(0.5 mg once daily) treatment (Fig. 1). The patients were
randomized (in a 1:1 ratio using a centralized procedure
and an interactive web response system) to groups that
either changed the treatment to telbivudine 600 mg once
daily (Telbivudine group) or continued the entecavir
treatment (Entecavir group) for 48 weeks.
The treatment assignments were generated by using a
permuted block size of four after stratification based on
serum HBsAg levels (1,000 − 5,000 vs. ≥5,000 IU/mL)
and the duration of the preceding entecavir treatment
(1–2 vs. ≥2 years). There was no interruption in enteca-
vir therapy before randomization. This study was
approved by the Institutional Review Board of the Asan
Medical Center, and written informed consent was
obtained from all study participants.
Study subjects
The patients were enrolled between July 2012 and
March 2013 at Asan Medical Center, an academic
tertiary referral hospital in Korea. Patients were consid-
ered eligible for enrollment if they were positive for the
HBeAg at the initiation of preceding entecavir treat-
ment, received entecavir for more than 1 year, had
undetectable serum HBV DNA levels (<60 IU/mL) on at
least two occasions more than 3 months apart, and
serum HBsAg levels >1,000 IU/mL at screening. Patients
were required to be between 18 and 80 years old and
have serum creatinine levels <1.5 mg/dL.
Patients were excluded if they met any of the following
criteria: history of interferon therapy; prior exposure to
oral antiviral agents other than entecavir for more than
1 week; evidence of decompensated liver disease; any
malignant neoplasm; suspicion of HCC; received organ
transplantation; concomitant use of immunosuppressive
agent; or co-infection with hepatitis C, hepatitis D, or
human immunodeficiency virus.
Efficacy and safety assessments
The primary efficacy endpoint of this study was defined as
a change in serum HBsAg levels from baseline to the end
of week 48. The secondary endpoints were the propor-
tions of patients with HBsAg loss/seroconversion, HBsAg
decline ≥0.5 log10 IU/mL, HBeAg loss/seroconversion in
those who were HBeAg-positive at randomization, and
the incidence of virologic breakthrough (increases in HBV
DNA levels ≥1 log10 IU/mL from nadir in two consecutive
tests). The probability of developing genotypic resistance
was assessed in all patients who experienced a virologic
breakthrough or had viremia (i.e., HBV DNA >60 IU/mL)
by the last time point of treatment and week 48.
Routine liver biochemistry, hepatitis B serology, and
serum HBV DNA measurements were assessed at week
12, 24, and 48 after randomization. During each visit,
patients were evaluated for adherence to study drugs by
counting the number of pills and empty blister packets
returned. The adverse events (clinical and laboratory)
were assessed throughout the 48 weeks.
Serum assays
The serum HBsAg levels were quantified by using the
Architect assay (Abbott Laboratories, Chicago, IL, USA),
which has a lower limit of detection (LLOD) of 0.05 IU/
mL. Serum HBV DNA levels were measured using a
Fig. 1 Patient flow diagram
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real-time PCR assay (linear dynamic detection range,
15 IU/mL to 1 × 109 IU/mL; Abbott Laboratories). Sero-
logical markers including anti-HBs, HBeAg, and anti-
HBe were determined by using enzyme immunoassays
(Abbott Laboratories) while resistance mutations were
determined by direct sequencing of the reverse
transcriptase domain (pol/RT) of the HBV polymerase
gene. The HBV genotype was not determined because
more than 98% of Korean patients with CHB have the
HBV genotype C2 [20].
Statistical analysis
The primary dataset for the efficacy and safety analyses
was defined as all randomized patients. All the analyses
were performed according to the intention-to-treat
principle. Patients who discontinued the study prior to
week 48 were considered failures for all endpoints from
the time of discontinuation. The efficacy and safety
analyses were performed by comparing the originally
randomized Telbivudine and Entecavir groups.
The primary efficacy endpoint was the change in serum
HBsAg levels at week 48. To observe a mean difference of
0.3 log10 IU/mL in the HBsAg decline between the Telbi-
vudine and Entecavir groups with a two-sided 5% signifi-
cance level and taking into account a dropout rate of up to
5%, an estimated 184 patients would have to be randomly
assigned to each group to achieve 80% power. However,
the study recruitment was discontinued after the inclusion
of 97 patients because of slow accrual and identifying the
significantly higher rate of virological breakthrough in the
Telbivudine group at interim analysis.
The between-group comparisons of the continuous or
categorical variables were conducted by using the t-test,
Chi-square test, or Fisher’s exact test, as deemed appropri-
ate. All the statistical analyses were performed by using
the statistical package for the social sciences (SPSS, ver-
sion 20, SPSS, Chicago, IL, USA) and R (version 3.0,
http://cran.r-project.org/). A P < 0.05 was considered
statistically significant.
Results
Baseline characteristics of patients
A total of 97 patients who had undetectable serum HBV
DNA following entecavir treatment were randomly
assigned to either the Telbivudine (n = 47) or Entecavir
group (n = 50) as shown in Fig. 1.
Treatment groups were comparable in baseline demo-
graphic and laboratory characteristics (Table 1). The
mean age was 47 years, and the population was predom-
inantly male (69.1%). The median level of HBsAg was
3.41 log10 IU/mL. All patients were HBeAg-positive at
the beginning of the preceding entecavir therapy; how-
ever, HBeAg positivity at randomization was 75.3%. All
patients had an undetectable HBV DNA and normal
alanine aminotransferase level. Thirty-four percent of
the patients had cirrhosis. The median duration of prior
entecavir treatment was 36 months.
Serologic responses
The mean change in serum HBsAg levels at week 48 of
the treatment was not significantly different between the
Telbivudine and Entecavir groups (−0.03 vs. -0.05 log10
Table 1 Baseline characteristics of the study patients
Characteristics Total (N = 97) Telbivudine (n = 47) Entecavir (n = 50)
Agea, years 47 ± 10 48 ± 11 47 ± 10
Male, n (%) 67 (69.1%) 32 (68.1%) 35 (70.0%)
HBsAgb, log10 IU/mL 3.41 (3.15-3.69) 3.43 (3.17-3.84) 3.40 (3.10-3.67)
HBeAg positivityc, n (%) 73 (75.3%) 40 (85.1%) 33 (66.0%)
HBV DNA undetectable (<60 IU/mL), n (%) 97 (100%) 47 (100%) 50 (100%)
ALTb, IU/L 20 (16–30) 24 (16–31) 19 (14–27)
Bilirubinb, mg/dL 1.0 (0.8-1.2) 1.0 (0.7-1.3) 1.0 (0.8-1.2)
Albuminb, g/dL 4.4 (4.2-4.5) 4.3 (4.1-4.5) 4.4 (4.2-4.5)
INRb 0.98 (0.95-1.04) 0.98 (0.95-1.03) 0.98 (0.95-1.04)
Plateletb, ×1,000/mm3 167 (134–208) 170 (129–207) 166 (137–209)
Cirrhosisd, n (%) 33 (34.0%) 15 (31.9%) 18 (36.0%)
Creatinineb, mg/dL 0.9 (0.7-1.0) 0.9 (0.7-1.0) 0.9 (0.8-1.0)
Creatine kinaseb, U/L 100 (77–129) 102 (81–156) 87 (72–116)
Duration of prior entecavir treatmentb, months 36 (24–46) 33 (24–42) 39 (23–47)
aMean ± standard deviation (SD)
bmedian (interquartile range)
cHBeAg positivity at randomization. All patients were HBeAg-positive at the beginning of preceding entecavir therapy
dCirrhosis was diagnosed by using ultrasonography with identification of liver surface nodularity and splenomegaly
HBsAg hepatitis B surface antigen, HBeAg hepatitis B envelope antigen, HBV hepatitis B virus, ALT alanine aminotransferase, INR international normalized ratio
An et al. BMC Gastroenterology  (2017) 17:15 Page 3 of 7
IU/mL; P = 0.57; Table 2 and Fig. 2). No patient experi-
enced HBsAg seroclearance or HBsAg decline >0.5 log10
IU/mL (Table 2). The proportion of patients who
achieved HBsAg decline >0.1 log10 IU/mL was not sig-
nificantly different between the Telbivudine and Enteca-
vir groups (23.4% vs. 30.0%; P = 0.46). The proportion of
HBeAg-positive patients who achieved HBeAg seroclear-
ance was low without any significant difference between
both groups at week 48 (5.0% vs. 15.2%; P = 0.14;
Table 2). The serologic response at week 48 was not sig-
nificantly different between the two groups by baseline
HBeAg positivity, status of cirrhosis, and gender. An
additional file showed these results in more detail [see
Additional file 1].
Virologic responses
Over the 48-week treatment period, 11 patients who
were all in the Telbivudine group experienced viro-
logic breakthrough (23.4%; P < 0.001; Table 2). All
those had good adherence to study medication (>95%).
Of these patients, genotypic resistance mutations to
Telbivudine (M204I +/− L180M) were detected in
seven during the virologic breakthrough. The detailed
characteristics of the 11 patients are shown in Add-
itional file 1. All of the patients recovered virologic re-
sponse in 12 weeks following the administration of
TDF or entecavir rescue therapy.
At week 48, the proportion of patients who maintained
the virologic response in the study was significantly lower
in the Telbivudine group than it was in the Entecavir
group (63.8% vs 98.0%; P < 0.001, Table 2 and Fig. 3).
Safety profiles
Three patients in the Telbivudine group discontinued
the study because of headache, gastrointestinal trouble,
and myopathy at week 1, 24, and 48, respectively. The
symptoms improved after switching the drug to enteca-
vir (Table 3). An elevation in serum creatine kinase (CK)
levels >3 times of upper limit of normal (ULN, 250 IU/
mL) was observed in three (6.4%) patients who all
belonged to the Telbivudine group. A patient in the Tel-
bivudine group experienced myopathy accompanied
with elevated CK (920 IU/L) at week 48. The symptom
improved and the serum CK level was normalized after
the telbivudine was discontinued.
Table 2 Serological, virological, and biochemical responses at week 48
Variables Telbivudine (n = 47) Entecavir (n = 50) P-value
Serologic Responses
Change in HBsAg level from baselinea,b, log10 IU/mL −0.03 ± 0.14 −0.05 ± 0.11 0.57
HBsAg levela, c, log10 IU/mL 3.37 (3.22 - 3.63) 3.39 (3.10 - 3.67) 0.65
HBsAg seroclearance, n (%) 0 (0%) 0 (0%) NA
HBsAg level decline from baseline >0.5 log10 IU/mL, n (%) 0 (0%) 0 (0%) NA
HBsAg level decline from baseline >0.1 log10 IU/mL, n (%) 11 (23.4%) 15 (30.0%) 0.46
HBeAg seroclearanced, n (%) 2/40 (5.0%) 5/33 (15.2%) 0.14
HBeAg seroconversiond, n (%) 0/40 (0%) 2/33 (6.1%) 0.11
Virologic Responses
Virologic breakthrough, n (%) 11 (23.4%) 0 (0%) <0.001
Genotypic resistance, n (%) 7 (14.9%) 0 (0%) 0.005
Virologic response at week 48, n (%) 30 (63.8%) 49 (98.0%) <0.001
Missing values were considered as failure for categorical endpoints
aAmong participants whose serum HBsAg and HBV DNA level at week 48 was available (n = 37 in the Telbivudine group, n = 49 in the Entecavir group)
bMean ± standard deviation (SD)
cMedian (interquartile range)
dAmong HBeAg-positive patients at randomization (n = 73)
HBsAg hepatitis B surface antigen, HBeAg hepatitis B envelope antigen, NA not applicable
Fig. 2 Changes in HBsAg levels from baseline
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Discussion
In this randomized trial, we found that in the patients
with HBeAg-positive CHB, who achieved undetectable
serum HBV DNA with the preceding entecavir treat-
ment, switching the treatment to telbivudine for
48 weeks was not associated with a greater reduction
in serum HBsAg levels. By contrast, telbivudine treat-
ment was associated with a 23.4% virologic break-
through and 14.9% genotypic resistance. None of the
patients in the Entecavir group experienced virologic
breakthrough or drug-resistance. Overall, the rate of
maintaining virologic response was significantly lower
in the Telbivudine group than that in the Entecavir
group at week 48.
To date, few head-to-head randomized trials have in-
vestigated whether various NUCs induce a decline in
HBsAg levels to different degrees. In HBeAg-positive pa-
tients, the rate of HBeAg seroconversion is only
approximately 20–35% even after long-term treatment
with a potent NUC such as entecavir or TDF [10, 21].
Furthermore, even after HBeAg-loss or -seroconversion
induced by a potent NUC, the suppression of serum
HBV DNA to undetectable levels is sustained only in
approximately 23–37% at 24 weeks after treatment is
discontinued. Therefore, HBsAg seroclearance is cur-
rently regarded as an optimal endpoint of treatment with
NUC [22, 23]. In fact, our previous study demonstrated
that HBsAg seroclearance achieved after NUC treatment
persists in most cases and is associated with favorable
clinical outcomes during long-term off-treatment follow-
up [5]. However, HBsAg seroclearance is very rarely
achievable, and almost life-long treatment is required in
most patients. Based on HBsAg kinetics, it has been esti-
mated that the predicted median time to HBsAg loss in
patients treated with lamivudine or entecavir is more
than 30–52 years [15, 24, 25]. A recent randomized trial
showed that even the combination of the potent NUCs,
entecavir and TDF, was not associated with greater
decline in HBsAg levels compared with entecavir mono-
therapy through 96 weeks of treatment.
It has been suggested that the decline in HBsAg levels
during lamivudine or entecavir therapy is slower and less
pronounced than it is during interferon treatment,
despite its higher suppression of HBV DNA [12, 15, 24].
Interestingly, experimental reports have suggested that
telbivudine shares some common clinical mechanisms of
action with interferon including dynamic changes in Th1/
Th2 type cytokines [26]. In a trial for patients with
Fig. 3 The proportion of patients maintaining virologic response
(HBV DNA <60 IU/mL) in the study. Patients who discontinued the
study prior to week 48 for any reason were considered failures in
virologic response at the time of discontinuation
Table 3 Safety profiles of the study patients
Adverse event category Telbivudine (n = 47) Entecavir (n = 50) P-value
Any adverse event 29 (61.7%) 29 (58.0%) 0.71
Serious adverse eventsa 2 (4.3%) 1 (2.0%) 0.52
Discontinuation due to adverse eventb 3 (6.4%) 0 0.11
Dose reduction due to adverse event 0 0 -
Deaths 0 0 -
Serum CK >3 x ULN 3 (6.4%) 0 0.11
Myopathy 1 (2.1%) 0 0.30
HCCc, n (%) 1 (2.1%) 0 0.30
Serum creatinine ≥0.5 mg/dL above baseline 0 0 -
eGFR <50 mL · min−1 · 1.73 m(2)-1 0 0 -
aTelbivudine group: cholangitis with intra-hepatic duct stone, hepatocellular carcinoma; Entecavir group: scrub typhus. None was determined to be related to
study drug administration
bBy headache, gastrointestinal issues, and myopathy (n = 1 each). The symptoms improved after discontinuation of the treatment
cHCC was diagnosed at week 36
CK creatine kinase, ULN upper limit of normal, HCC hepatocellular carcinoma, eGFR estimated glomerular filtration rate
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HBeAg-positive CHB who received telbivudine treatment
for up to 3 years and maintained undetectable serum
HBV DNA level, up to 71 and 57% of the patients
achieved HBeAg-loss and HBeAg seroconversion, respect-
ively [16]. Another trial consisting of treatment-naïve pa-
tients with HBeAg-positive CHB revealed that the rate of
patients with rapid HBsAg decline (≥0.5 log10 IU/mL) in
the telbivudine monotherapy group (41%) was comparable
to that in the PEG-IFN monotherapy group (31%) [14].
An observational study in Hong Kong including various
NUC-treated patients with an initial immune active phase
showed a significant reduction of HBsAg only in the telbi-
vudine treatment group [17]. Although it is well known
that telbivudine is associated with a higher rate of drug-
resistance, previous studies identified the association of
early profound viral suppression with a very low rate of
drug resistance during long-term treatment. In patients
who achieved HBV DNA levels undetectable in the quan-
titative PCR assay at week 24, the resistance risk at week
104 was only 4% [19]. However, the results of our current
study contrast strikingly with our hypothesis. Switching
the treatment of patients with virologic response induced
by preceding entecavir treatment to telbivudine was asso-
ciated with an unacceptably high rate of virologic break-
through and drug-resistance without any beneficial effect
on the HBsAg decline. This rate of virologic breakthrough
(23.4%) during the 48-week telbivudine therapy in this
study was comparable to that in a previous trial, which
showed a 28.8% virologic breakthrough during a 2-year
telbivudine treatment regimen in patients who were
HBeAg-positive [19]. This observed rate is also similar to
the rate of virologic rebound (24%) observed during lami-
vudine treatment in patients who had achieved undetect-
able serum HBV DNA following the preceding entecavir
treatment [27].
The majority of our study patients did not exhibit
HBeAg-seroclearance after the preceding >1-year ente-
cavir therapy, which might have hindered the observa-
tion of a decline in the HBsAg levels. The HBsAg levels
have been shown to decline rapidly during the first year
of treatment [28]. Moreover, in HBeAg-positive patients,
the decline in serum HBsAg is mainly confined to those
who experience a clearance of HBeAg by either PEG-
IFN or entecavir treatment [12]. However, because a
high serum HBV DNA level is a strong predictor of the
development of telbivudine-resistance, comparing telbi-
vudine and entecavir in treatment-naïve patients could
not be ethically justified.
This study has several limitations that are worth men-
tioning. First, the small sample size and short duration
may have decreased the statistical power of the study to
observe the differences in the decline of HBsAg levels
between the Telbivudine and Entecavir groups. Never-
theless, the significantly higher rate of virologic
breakthrough in the Telbivudine group did not justify
the continuation of the study. Second, this was an open-
label study and blinding was not performed. Although
objective endpoints (serologic and virologic determina-
tions) were used and drug adherence was ascertained,
the lack of blinding might have influenced the response
of the study patients or biased the investigators in
reporting the adherence and adverse events. Lastly, the
HBV genotype of our study patients was not determined.
This was because one of the inclusion criteria of this
study was an undetectable serum HBV DNA level at
screening. However, since almost all Korean patients
with CHB have the C HBV genotype [29], the applica-
tion of the results of this study may be limited, and not
extrapolatable to patients with other HBV genotypes.
Conclusions
In conclusion, in patients who have achieved undetect-
able serum HBV DNA by entecavir treatment, switching
the treatment to telbivudine for 48 weeks resulted in an
unacceptably high rate of virologic breakthrough and
drug-resistance without any beneficial effect on HBsAg
decline. Prior viral suppression by entecavir did not con-
fer any significant advantage to patients who switched to
telbivudine. These results do not support the use of low
genetic barrier drugs as a switch treatment strategy in
patients who achieve virologic response by high genetic
barrier drugs.
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rhosis. Table S3. Serological, virological, and biochemical responses at
week 48 by gender. Table S4. Characteristics of the patients at virologic
breakthrough. (DOCX 51 kb)
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